IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
This study has been completed.
Sponsor:
Abbott
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00195689
First received: September 13, 2005
Last updated: August 28, 2007
Last verified: August 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
| Condition | Intervention | Phase |
|---|---|---|
| Psoriatic Arthritis | Biological: Human anti-TNF monoclonal antibody/adalimumab | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis |
Resource links provided by NLM:
Genetics Home Reference related topics:
psoriatic arthritis
Drug Information available for:
Adalimumab
U.S. FDA Resources
Further study details as provided by Abbott:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject completed study M02-518 or M02-570
Exclusion Criteria:
-
Subject prematurely discontinued study M02-518 or M02-570
- Female subject who is pregnant or breast-feeding or considering becoming pregnant
- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195689
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195689
Locations
| United States, Illinois | |
| Global Medical Information-Abbott Laboratories | |
| Abbott Park, Illinois, United States, 60064 | |
Sponsors and Collaborators
Abbott
Investigators
| Study Director: | Beverly Paperiello | Abbott |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00195689 History of Changes |
| Other Study ID Numbers: |
M02-537 |
| Study First Received: | September 13, 2005 |
| Last Updated: | August 28, 2007 |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Psoriatic Joint Diseases Musculoskeletal Diseases Spondylarthropathies Spondylarthritis Spondylitis Spinal Diseases Bone Diseases Psoriasis |
Skin Diseases, Papulosquamous Skin Diseases Antibodies Immunoglobulins Antibodies, Monoclonal Adalimumab Immunologic Factors Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on July 25, 2017